Skip to main content

Table 1 Clinicopathological features of subgroups

From: Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer

Variable Subgroup P-value
PD-L1-high-actived PD-L1-high-Exhausted PD-L1-low-actived PD-L1-low-Exhausted
Age 64.43 (11.24) 68.37 (10.05) 64.89 (9.75) 71.84 (9.36) < 0.0001
BMI 26.98 (5.29) 27.31 (5.79) 26.44 (5.80) 26.90 (5.73) < 0.0001
Sex      0.567
 female 16 (23.9%) 33 (29.7%) 20 (21.3%) 22 (25.9%)  
 male 51 (76.1%) 78 (70.3%) 74 (78.7%) 63 (74.1%)  
Race      < 0.0001
 Asian 6 (9.0%) 6 (5.4%) 24 (25.5%) 6 (7.1%)  
 Black 2 (3.0%) 7 (6.3%) 5 (5.3%) 3 (3.5%)  
 White 56 (83.6%) 96 (86.5%) 57 (60.6%) 73 (85.9%)  
 Not report 3 (4.5%) 2 (1.8%) 8 (8.5%) 3 (3.5%)  
Lymphovascular      0.106
 Yes 26 (38.8%) 39 (35.1%) 26 (27.7%) 41 (48.2%)  
 No 22 (32.8%) 41 (36.9%) 32 (34.0%) 20 (23.5%)  
 Not report 19 (28.4%) 31 (27.9%) 36 (38.3%) 24 (28.2%)  
Stage      < 0.0001
 Stage I 1 (1.5%) 0 (0%) 2 (2.1%) 0 (0%)  
 Stage II 28 (41.8%) 24 (21.6%) 47 (50.0%) 15 (17.6%)  
 Stage III 19 (28.4%) 46 (41.4%) 22 (23.4%) 33 (38.8%)  
 Stage IV 18 (26.9%) 41 (36.9%) 22 (23.4%) 37 (43.5%)  
 Not report 1 (1.5%) 0 (0%) 1 (1.1%) 0 (0%)  
CMC subtype      < 0.0001
 Basal squamous 33 (49.3%) 75 (67.6%) 6 (6.4%) 8 (9.4%)  
 Luminal 2 (3.0%) 3 (2.7%) 3 (3.2%) 17 (20.0%)  
 Luminal infiltrated 4 (6.0%) 24 (21.6%) 2 (2.1%) 34 (40.0%)  
 Luminal papillary 23 (34.3%) 7 (6.3%) 76 (80.9%) 23 (27.1%)  
 Neuronal 5 (7.5%) 2 (1.8%) 7 (7.4%) 3 (3.5%)  
 PD-L1 2.29 (1.11) 2.32 (1.09) 0.47 (0.25) 0.56 (0.25) < 0.0001
  1. a. ANOVA; b. Chi-square test (and Fisher’s exact test when appropriate)
  2. Abbreviations: Lymphovascular lymphovascular invasion present